Key points
- FY26 marked significant transition from clinical development to commercial execution
- SPONTAN®'s real-world footprint in Australia exceeded 1,000 prescriptions
- Secured exclusive US telehealth distribution and pharmacy fulfillment agreements
- Diversified into gastroenterology with OROFLOW® and invested in LevOmega
- Ended the year with $19.6 million in cash, no debt
Full summary
LTR Pharma's 2026 Annual Report highlights a significant transition from clinical development to commercial execution. The report details the real-world evidence for SPONTAN®, LTR Pharma's lead product, which exceeded 1,000 prescriptions in Australia. The company secured exclusive US telehealth distribution and pharmacy fulfillment agreements, marking an important milestone in its US market entry strategy. Additionally, LTR Pharma diversified into gastroenterology with OROFLOW®, an investigational therapy for oesophageal motility disorders, and invested in LevOmega, a biotechnology company developing omega-3 ingredients. The report concludes with the company's financial position, ending the year with $19.6 million in cash and no debt.
Outlook
LTR Pharma is poised to leverage its proprietary intranasal drug delivery platform to address multiple therapeutic areas, with a focus on commercial execution and market expansion.